Delivery of AAV2-CYP2J2 protects remnant kidney in the 5/6-nephrectomized rat via inhibition of apoptosis and fibrosis

Human Gene Therapy

Volumn 23, Issue 7, 2012, Pages 688-699

  Zhao, Gang ^a   Tu, Ling ^a   Li, Xuguang ^a   Yang, Shenglan ^a   Chen, Chen ^a   Xu, Xizhen ^a   Wang, Peihua ^a   Wang, Dao Wen ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; COLLAGEN TYPE 1; COLLAGEN TYPE 4; CREATININE; CYTOCHROME P450 2J2; EPOXYICOSATRIENOIC ACID; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BAX; PROTEIN BCL 2; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD PRESSURE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE MODEL; FIBROSIS; GENE TARGETING; GLOMERULOSCLEROSIS; HUMAN; HUMAN CELL; IN VIVO STUDY; KIDNEY CELL; KIDNEY INJURY; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; NEPHRECTOMY; NICK END LABELING; NONHUMAN; PROTEIN EXPRESSION; PROTEINURIA; RAT; UREA NITROGEN BLOOD LEVEL;

8,11,14-EICOSATRIENOIC ACID; ANIMALS; APOPTOSIS; BLOOD PRESSURE; COLLAGEN; CYTOCHROME P-450 ENZYME SYSTEM; DEPENDOVIRUS; FIBROSIS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; KIDNEY; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MITOGEN-ACTIVATED PROTEIN KINASES; NEPHRECTOMY; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; RENAL INSUFFICIENCY, CHRONIC; SMAD PROTEINS;

ADENO-ASSOCIATED VIRUS; RATTUS;

EID: 84864365143     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2011.135     Document Type: Article

References (47)

1. Athirakul, K., Bradbury, J.A., Graves, J.P., et al. (2008). Increased blood pressure in mice lacking cytochrome P450 2J5. FASEB J. 22, 4096-4108.
2. Benigni, A., and Remuzzi, G. (2008). Gene Therapy for Renal Diseases and Transplantation. (Karger, Basel).
3. Capdevila, J.H., Falck, J.R., and Harris, R.C. (2000). Cytochrome P450 and arachidonic acid bioactivation: Molecular and functional properties of the arachidonate monooxygenase. J. Lipid Res. 41, 163-181. (Pubitemid 30117856)
4. Chen, C., Li, G., Liao, W., et al. (2009). Selective inhibitors of CYP2J2 related to terfenadine exhibit strong activity against human cancers in vitro and in vivo. J. Pharmacol. Exp. Ther. 329, 908-918.
5. Chen, J.K., Falck, J.R., Reddy, K.M., et al. (1998). Epoxyeicosatrienoic acids and their sulfonimide derivatives stimulate tyrosine phosphorylation and induce mitogenesis in renal epithelial cells. J. Biol. Chem. 273, 29254-29261. (Pubitemid 28507627)
6. Chen, J.K., Capdevila, J., and Harris, R.C. (2000). Overexpression of C-terminal Src kinase blocks 14, 15-epoxyeicosatrienoic acid-induced tyrosine phosphorylation and mitogenesis. J. Biol. Chem. 275, 13789-13792. (Pubitemid 30257451)
7. Chen, J.K., Capdevila, J., and Harris, R.C. (2002). Heparinbinding EGF-like growth factor mediates the biological effects of P450 arachidonate epoxygenase metabolites in epithelial cells. Proc. Natl. Acad. Sci. U.S.A. 99, 6029-6034. (Pubitemid 34493259)
8. Cummings, B.S., and Schnellmann, R.G. (2002). Cisplatininduced renal cell apoptosis: Caspase 3-dependent and-independent pathways. J. Pharmacol. Exp. Ther. 302, 8-17. (Pubitemid 34680415)
9. Fornage, M., Hinojos, C.A., Nurowska, B.W., et al. (2002). Polymorphism in soluble epoxide hydrolase and blood pressure in spontaneously hypertensive rats. Hypertension 40, 485-490.
10. Griffin, K.A., Picken, M., and Bidani, A.K. (1994). Method of renal mass reduction is a critical modulator of subsequent hypertension and glomerular injury. J. Am. Soc. Nephrol. 4, 2023-2031. (Pubitemid 24977009)
11. Hinojosa-Laborde, C., Frohlich, B.H., and Cowley, A.W., Jr. (1992). Whole body autoregulation in reduced renal mass hypertension. Hypertension 20, 659-665.
12. Imig, J.D. (2005). Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am. J. Physiol. Renal Physiol. 289, F496-F503. (Pubitemid 41208461)
13. Imig, J.D., Zhao, X., Zaharis, C.Z., et al. (2005). An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension 46, 975-981.
14. Javelaud, D., and Mauviel, A. (2004). Mammalian transforming growth factor-bs: Smad signaling and physio-pathological roles. Int. J. Biochem. Cell Biol. 36, 1161-1165. (Pubitemid 38515657)
15. Jung, O., Brandes, R.P., Kim, I.H., et al. (2005). Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension. Hypertension 45, 759-765. (Pubitemid 40418378)
16. Kaergel, E., Muller, D.N., Honeck, H., et al. (2002). P450-dependent arachidonic acid metabolism and angiotensin II-induced renal damage. Hypertension 40, 273-279. (Pubitemid 35006710)
17. Klahr, S., and Morrissey, J. (2003). Progression of chronic renal disease. Am. J. Kidney Dis. 41, S3-S7. (Pubitemid 36278335)
18. Kunduzova, O.R., Bianchi, P., Pizzinat, N., et al. (2002). Regulation of JNK/ERK activation, cell apoptosis, and tissue regeneration by monoamine oxidases after renal ischemia-reperfusion. FASEB J. 16, 1129-1131.
19. Kunduzova, O.R., Escourrou, G., Seguelas, M.H., et al. (2003). Prevention of apoptotic and necrotic cell death, caspase-3 activation, and renal dysfunction by melatonin after ischemia/reperfusion. FASEB J. 17, 872-874.
20. Larsen, B.T., Miura, H., Hatoum, O.A., et al. (2006). Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BK(Ca) channels: Implications for soluble epoxide hydrolase inhibition. Am. J. Physiol. Heart Circ. Physiol. 290, H491-H499.
21. Lee, C.R., Imig, J.D., Edin, M.L., et al. (2010). Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice. FASEB J. 24, 3770-3781.
22. Li, C., Lim, S.W., Sun, B.K., et al. (2004). Expression of apoptosisrelated factors in chronic cyclosporine nephrotoxicity after cyclosporine withdrawal. Acta Pharmacol. Sin. 25, 401-411. (Pubitemid 38470406)
23. Li, M., Georgakopoulos, D., Lu, G., et al. (2005). p38 MAP kinase mediates inflammatory cytokine induction in cardiomyocytes and extracellular matrix remodeling in heart. Circulation 111, 2494-2502. (Pubitemid 40696138)
24. Liu, Y. (2006). Renal fibrosis: New insights into the pathogenesis and therapeutics. Kidney Int. 69, 213-217. (Pubitemid 43323069)
25. Loch, D., Hoey, A., Morisseau, C., et al. (2007). Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydrolase. Cell Biochem. Biophys. 47, 87-98.
26. Michaelis, U.R., Fisslthaler, B., Medhora, M., et al. (2003). Cytochrome P450 2C9-derived epoxyeicosatrienoic acids induce angiogenesis via cross-talk with the epidermal growth factor receptor (EGFR). FASEB J. 17, 770-772.
27. Milz, S., McNeilly, C., Putz, R., et al. (1998). Fibrocartilages in the extensor tendons of the interphalangeal joints of human toes. Anat. Rec. 252, 264-270. (Pubitemid 28440910)
28. Minuz, P., Jiang, H., Fava, C., et al. (2008). Altered release of cytochrome P450 metabolites of arachidonic acid in renovascular disease. Hypertension 51, 1379-1385. (Pubitemid 351555953)
29. Nakagawa, K., Holla, V.R., Wei, Y., et al. (2006). Salt-sensitive hypertension is associated with dysfunctional Cyp4a10 gene and kidney epithelial sodium channel. J. Clin. Invest. 116, 1696-1702.
30. Nathwani, A.C., Tuddenham, E.G., Rangarajan, S., et al. (2011). Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med. 365, 2357-2365.
31. Node, K., Ruan, X.L., Dai, J., et al. (2001). Activation of Gas mediates induction of tissue-type plasminogen activator gene transcription by epoxyeicosatrienoic acids. J. Biol. Chem. 276, 15983-15989.
32. Petrich, B.G., Eloff, B.C., Lerner, D.L., et al. (2004). Targeted activation of c-Jun N-terminal kinase in vivo induces restrictive cardiomyopathy and conduction defects. J. Biol. Chem. 279, 15330-15338. (Pubitemid 38618931)
33. Raij, L., Azar, S., and Keane, W. (1984). Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats. Kidney Int. 26, 137-143. (Pubitemid 14017051)
34. Roman, R.J. (2002). P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol. Rev. 82, 131-185. (Pubitemid 34654217)
35. Satoh, M., Kashihara, N., Fujimoto, S., et al. (2003). A novel free radical scavenger, edarabone, protects against cisplatininduced acute renal damage in vitro and in vivo. J. Pharmacol. Exp. Ther. 305, 1183-1190. (Pubitemid 36617997)
36. Shi, Y. (2001). A structural view of mitochondria-mediated apoptosis. Nat. Struct. Biol. 8, 394-401. (Pubitemid 32381284)
37. Silver, J.N., Elder, M., Conlon, T., et al. (2011). Recombinant adeno-associated virus-mediated gene transfer for the potential therapy of adenosine deaminase-deficient severe combined immune deficiency. Hum. Gene Ther. 22, 935-949.
38. Simpkins, A.N., Rudic, R.D., Schreihofer, D.A., et al. (2009). Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection. Am. J. Pathol. 174, 2086-2095.
39. Tu, L., Xu, X., Wan, H., et al. (2008). Delivery of recombinant adeno-associated virus-mediated human tissue kallikrein for therapy of chronic renal failure in rats. Hum. Gene Ther. 19, 318-330. (Pubitemid 351591428)
40. Wang, T., Li, H., Zhao, C., et al. (2004). Recombinant adenoassociated virus-mediated kallikrein gene therapy reduces hypertension and attenuates its cardiovascular injuries. Gene Ther. 11, 1342-1350. (Pubitemid 39213999)
41. Wu, S., Chen, W., Murphy, E., et al. (1997). Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes. J. Biol. Chem. 272, 12551-12559. (Pubitemid 27203348)
42. Xiao, B., Li, X., Yan, J., et al. (2010). Overexpression of cytochrome P450 epoxygenases prevents development of hypertension in spontaneously hypertensive rats by enhancing atrial natriuretic peptide. J. Pharmacol. Exp. Ther. 334, 784-794.
43. Yan, W., Wang, P., Zhao, C.X., et al. (2009). Decorin gene delivery inhibits cardiac fibrosis in spontaneously hypertensive rats by modulation of transforming growth factor-b/Smad and p38 mitogen-activated protein kinase signaling pathways. Hum. Gene Ther. 20, 1190-200.
44. Yuan, G., Deng, J., Wang, T., et al. (2007). Tissue kallikrein reverses insulin resistance and attenuates nephropathy in diabetic rats by activation of phosphatidylinositol 3-kinase/protein kinase B and adenosine 5¢-monophosphate-activated protein kinase signaling pathways. Endocrinology 148, 2016-2026. (Pubitemid 46997049)
45. Zeldin, D.C., Foley, J., Goldsworthy, S.M., et al. (1997). CYP2J subfamily cytochrome P450s in the gastrointestinal tract: Expression, localization, and potential functional significance. Mol. Pharmacol. 51, 931-943. (Pubitemid 27249126)
46. Zhao, C., Wang, P., Xiao, X., et al. (2003). Gene therapy with human tissue kallikrein reduces hypertension and hyperinsulinemia in fructose-induced hypertensive rats. Hypertension 42, 1026-1033. (Pubitemid 37413748)
47. Zincarelli, C., Soltys, S., Rengo, G., and Rabinowitz, J.E. (2008). Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol. Ther. 16, 1073-1080. (Pubitemid 351737072)